

U.S. Biosimilars Market – A Deep Dive

Aiswariya Chidambaram,

Senior Analyst

1. The U.S. biosimilars market is projected to reach \$10 billion by 2025, up from \$2 billion in 2015. This growth is driven by the increasing number of biosimilars approved by the FDA, which has streamlined the regulatory process. Key players in the market include Amgen, AbbVie, and Biogen, who are investing heavily in R&D to develop new biosimilars. The market is also being driven by the need for cost-effective treatments, as biosimilars are significantly cheaper than their reference biologics. The U.S. government is also pushing for more biosimilars to reduce healthcare costs. The market is expected to continue to grow rapidly in the coming years, as more biosimilars are approved and marketed.

Biography

Aiswariya Chidambaram is a Senior Analyst at the U.S. Biosimilars Market. She has over 10 years of experience in the pharmaceutical industry, with a focus on biosimilars. She has worked for several leading pharmaceutical companies, where she was responsible for market research, competitive analysis, and strategic planning. She has a Master's degree in Business Administration from a top-tier university. She is a frequent speaker at industry conferences and has published several articles on biosimilars. She is also a member of several professional organizations, including the Pharmaceutical Research and Manufacturers of America (PhRMA) and the American Pharmaceutical Association (APHA). She is currently based in New York City and can be reached at aiswariya.chidambaram@pharma.com.